An RNA aptamer that specifically binds pancreatic adenocarcinoma up-regulated factor inhibits migration and growth of pancreatic cancer cells

Cancer Letters

Volumn 313, Issue 1, 2011, Pages 76-83

  Kim, Yun Hee ^a   Sung, Ho Jin ^a,b   Kim, Sukyoung ^a   Kim, Eun Ok ^a   Lee, Ji Won ^a   Moon, Ju Young ^a   Choi, Kyungho ^a   Jung, Ji Eun ^a   Lee, Yangsoon ^c   Koh, Sang Seok ^c   Rhee, Sue Goo ^b   Heo, Kyun ^a   Kim, In Hoo ^a  

^a National Cancer Center   (South Korea)

^b Ewha Womans University   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Anticancer drug; Aptamer; Pancreatic cancer; PAUF; SELEX

Indexed keywords

ANTINEOPLASTIC AGENT; APTAMER; P12FR2; PANCREATIC ADENOCARCINOMA UP REGULATED FACTOR; SECRETORY PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; HUMANS; LECTINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; PANCREATIC NEOPLASMS; PROTEIN BINDING; THYMIDINE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 80054097776     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.08.027     Document Type: Article

References (31)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
2. Chames P., Kerfelec B., Baty D. Therapeutic antibodies for the treatment of pancreatic cancer. ScientificWorldJournal 2010, 10:1107-1120.
3. Smeenk H.G., Tran T.C., Erdmann J., van Eijck C.H., Jeekel J. Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?. Langenbecks Arch. Surg. 2005, 390:94-103.
4. Ueno H., Kosuge T. Adjuvant treatments for resectable pancreatic cancer. J. Hepatobil. Pancreat. Surg. 2008, 15:468-472.
5. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., Nelson R., Dorr F.A., Stephens C.D., Von Hoff D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
6. Wong H.H., Lemoine N.R. Novel therapies for pancreatic cancer: setbacks and progress. Future Oncol. 2010, 6:1061-1064.
7. Heinemann V., Philip P.A., Pelzer U. Accomplishments in 2008 in the treatment of metastatic pancreatic cancer. Gastrointest. Cancer Re. 2009, 3:S43-S47.
8. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., Au H.J., Murawa P., Walde D., Wolff R.A., Campos D., Lim R., Ding K., Clark G., Voskoglou-Nomikos T., Ptasynski M., Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007, 25:1960-1966.
9. Kim S.A., Lee Y., Jung D.E., Park K.H., Park J.Y., Gang J., Jeon S.B., Park E.C., Kim Y.G., Lee B., Liu Q., Zeng W., Yeramilli S., Lee S., Koh S.S., Song S.Y. Pancreatic adenocarcinoma up-regulated factor (PAUF), a novel up-regulated secretory protein in pancreatic ductal adenocarcinoma. Cancer Sci. 2009, 100:828-836.
10. Lee Y., Kim S.J., Park H.D., Park E.H., Huang S.M., Jeon S.B., Kim J.M., Lim D.S., Koh S.S. PAUF functions in the metastasis of human pancreatic cancer cells and upregulates CXCR4 expression. Oncogene 2010, 29:56-67.
11. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
12. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
13. Lee J.F., Stovall G.M., Ellington A.D. Curr. Opin. Chem. Biol. 2006, 10:282-289.
14. Blank M., Blind M. Aptamers as tools for target validation. Curr. Opin. Chem. Biol. 2005, 9:336-342.
15. Yan A.C., Levy M. Aptamers and aptamer targeted delivery. RNA Biol. 2009, 6:316-320.
16. Pestourie C., Tavitian B., Duconge F. Aptamers against extracellular targets for in vivo applications. Biochimie 2005, 87:921-930.
17. Kang Y., Wang F., Feng J., Yang D., Yang X., Yan X. Knockdown of CD146 reduces the migration and proliferation of human endothelial cells. Cell Res. 2006, 16:313-318.
18. Ruckman J., Green L.S., Beeson J., Waugh S., Gillette W.L., Henninger D.D., Claesson-Welsh L., Janjić N. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem. 1998, 273:20556-20567.
19. Stan S.D., Singh S.V., Brand R.E. Chemoprevention strategies for pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:347-356.
20. Karapanos K., Nomikos N. Current surgical aspects of palliative treatment for unresectable pancreatic cancer. Cancers (Basel) 2011, 3:636-651.
21. Helm J.F., Centeno B.A., Coppola D., Druta M., Park J.Y., Chen D.T., Hodul P.J., Kvols L.K., Yeatman T.J., Carey L.C., Karl R.C., Malafa M.P. Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution. Cancer Control 2008, 15:288-294.
22. Hui Y.F., Reitz J. Gemcitabine: a cytidine analogue active against solid tumors. Am. J. Health Syst. Pharm. 1997, 54:162-170.
23. Iwasaki H., Huang P., Keating M.J., Plunkett W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 1997, 90:270-278.
24. Davidson J.D., Ma L., Flagella M., Geeganage S., Gelbert L.M., Slapak C.A. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 2004, 64:3761-3766.
25. Rosell R., Danenberg K.D., Alberola V., Bepler G., Sanchez J.J., Camps C., Provencio M., Isla D., Taron M., Diz P., Artal A. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin. Cancer Res. 2004, 10:1318-1325.
26. Bergman A.M., Eijk P.P., Ruiz van Haperen V.W., Smid K., Veerman G., Hubeek I., van den Ijssel P., Ylstra B., Peters G.J. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res. 2005, 65:9510-9516.
27. Bayraktar S., Bayraktar U.D., Rocha-Lima C.M. Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer. World J. Gastroenterol. 2010, 16:673-682.
28. Park H.D., Lee Y., Oh Y.K., Jung J.G., Park Y.W., Myung K., Kim K.H., Koh S.S., Lim D.S. Pancreatic adenocarcinoma upregulated factor promotes metastasis by regulating TLR/CXCR4 activation. Oncogene 2011, 30:201-211.
29. Green L.S., Jellinek D., Bell C., Beebe L.A., Feistner B.D., Gill S.C., Jucker F.M., Janjić N. Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem. Biol. 1995, 2:683-695.
30. Gragoudas E.S., Adamis A.P., Cunningham E.T., Feinsod M., Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. New Engl. J. Med. 2004, 351:2805-2816.
31. Bunka D.H., Platonova O., Stockley P.G. Development of aptamer therapeutics. Curr. Opin. Pharmacol. 2010, 10:557-562.